Aim: To determine the relationship between depressive symptoms and insomnia with therapeutic non-adherence and metabolic control in patients with T2DM.

Methods: Observational, descriptive, cross-sectional study with analytical component. Adult patients with DM2 treated in an Endocrinology Service of a University Hospital of Asunción-Paraguay from May to October 2022. The Morinsky-Green adherence questionnaires, the Insomnia Severity Index (ISI), the Patient Health Questionnaire 9 (PHQ-9) and predetermined questionnaire for clinical characteristics where used.

Results: 171 patients were studied. Women: 69%. Mean age 54.9 ± 11.8 years. Symptoms of depression occurred in 61.9%. 59% suffered insomnia. The 64.3% of patients had moderate non-adherence. The mean HbA1c was 8.08 ± 0.16 %. Inadequate metabolic control (HbA1c >7%) was seen in 68% of patients. A relationship was found between depression and insomnia (p<0,001), in addition to the fact that the worse adherence the more depressive symptoms (p<0,001) and the more insomnia (p <0.001).Patients with poor metabolic control have more depressive symptoms (p=0,005) and insomnia (p=0,009).

Conclusion: Depressive symptoms were significantly related to non-adherence to treatment and to worse metabolic control, but not the presence of insomnia without depressive symptoms.


M.N.Escobar: None. A.I.Ramirez: None. E.D.Bueno colman: None. A.Benitez: None. M.Palacios: Speaker's Bureau; Sanofi. J.T.Jimenez: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at